標(biāo)題: Titlebook: Cardiovascular Regenerative Medicine; Tissue Engineering a Vahid Serpooshan,Sean M. Wu Book 2019 Springer Nature Switzerland AG 2019 3D bio [打印本頁(yè)] 作者: 天真無(wú)邪 時(shí)間: 2025-3-21 18:47
書目名稱Cardiovascular Regenerative Medicine影響因子(影響力)
作者: 不安 時(shí)間: 2025-3-21 23:37 作者: 共同給與 時(shí)間: 2025-3-22 02:55
Decellularized Extracellular Matrix-Based Cardiovascular Tissue Engineering,nt therapies are restricted to pharmaceuticals, mechanical and electrical support devices, and synthetic materials. Decellularized extracellular matrices have strong potential to provide support to failing myocardium. Their native composition offers complex biochemical cues beyond what can be synthe作者: 開始沒有 時(shí)間: 2025-3-22 05:48 作者: interior 時(shí)間: 2025-3-22 11:09
Nanobiomaterial Advances in Cardiovascular Tissue Engineering,rgoing current treatment modalities is bleak, due to the lack of regenerative capacity of native heart tissue. Tissue engineering and regenerative medicine have developed numerous strategies to repair or replace injured myocardium. One of the most promising strategies to date is the attempt to engin作者: 無(wú)能的人 時(shí)間: 2025-3-22 14:24
Bioengineering 3D Cardiac Microtissues Using Bioassembly, method that is used for the generation of defined biological products from living cells, biomaterials, bioactive molecules, and extracellular matrices. As one of the mainstream technical routes in biofabrication, bioassembly has been widely used for generating 3D cardiac microtissues. In this chapt作者: 無(wú)能的人 時(shí)間: 2025-3-22 20:00 作者: ASSET 時(shí)間: 2025-3-23 01:00
Cardiac Patch-Based Therapies of Ischemic Heart Injuries,ile a number of cell- and cardiac tissue-based therapies can limit this dysfunction, the proportion of cells that survive at the recipient heart for more than a few weeks after transplantation is extremely low. Consequently, substantial remuscularization of the infarcted region has rarely been repor作者: insurgent 時(shí)間: 2025-3-23 02:13 作者: puzzle 時(shí)間: 2025-3-23 09:02
Injectable Hydrogels to Treat Myocardial Infarction,d fibrosis and ultimately reduces cardiac function dramatically. While some drug therapies such as diuretics, ACE inhibitors, and beta-blockers may initially help to treat symptoms of developing heart failure, late stage patients require more invasive surgical procedures such as heart transplantatio作者: 不出名 時(shí)間: 2025-3-23 12:29
Regenerative Medicine for the Treatment of Congenital Heart Disease,ticular population. Physicians now have a broad range of therapeutic option: medical therapy, interventional procedures, or surgery. Nevertheless, shortcomings remain. The ongoing developments in regenerative medicine pave the way toward a new area in the management of CHD, especially regarding surg作者: 真 時(shí)間: 2025-3-23 16:45 作者: HACK 時(shí)間: 2025-3-23 22:07 作者: 組成 時(shí)間: 2025-3-24 01:31 作者: Obstruction 時(shí)間: 2025-3-24 03:55 作者: HAUNT 時(shí)間: 2025-3-24 07:30
https://doi.org/10.1007/978-94-015-9578-0neering strategies represent an important class of therapeutics which aim to address the insufficiencies of current management of heart failure and related sequelae. Here, we review the various tissue engineering strategies which address the limitations of current therapies and represent promising adjunct treatments to the current gold standard.作者: 玉米 時(shí)間: 2025-3-24 14:45 作者: ordain 時(shí)間: 2025-3-24 18:33
3D Bioprinting of Cardiovascular Tissue Constructs: Cardiac Bioinks,ivo applications. Hydrogel-based bioinks must fulfill several key biophysical and biochemical requirements, before, during, and post-printing processes. This chapter explores in depth the parameters that are necessary for a successful bioink solution that can support cardiac tissue structure and function.作者: conscribe 時(shí)間: 2025-3-24 21:07
Tissue-Engineered Stem Cell Models of Cardiovascular Diseases,erated to create culture systems that better recapitulate the complex 3D microenvironments found in living tissue. By using these engineered models, more relevant data may be produced to unravel the molecular underpinnings of disease states and potentially translate into new therapeutic strategies.作者: 尖叫 時(shí)間: 2025-3-25 01:23 作者: Ostrich 時(shí)間: 2025-3-25 04:46
https://doi.org/10.1007/978-94-015-9578-0ical applications are also discussed. This chapter is suitable for postgraduate and undergraduate students as well as clinicians and medical researchers who are interested in bioengineering and wish to obtain a fundamental understanding of bioassembly approaches for the fabrication of 3D cardiac microtissues.作者: 注視 時(shí)間: 2025-3-25 10:44
Some new results in summability theory,s of action from these studies are also discussed. It is hopeful that this direction of research may one day lead to better therapeutic modalities for postinfarction left ventricular (LV) remodeling and heart failure.作者: 作繭自縛 時(shí)間: 2025-3-25 12:58 作者: Override 時(shí)間: 2025-3-25 18:44 作者: Spinal-Fusion 時(shí)間: 2025-3-25 23:24 作者: 骨 時(shí)間: 2025-3-26 03:38
Cardiac Patch-Based Therapies of Ischemic Heart Injuries,s of action from these studies are also discussed. It is hopeful that this direction of research may one day lead to better therapeutic modalities for postinfarction left ventricular (LV) remodeling and heart failure.作者: Eosinophils 時(shí)間: 2025-3-26 04:55
Cell-Based Cardiovascular Regenerative Therapies, regenerative therapy, such as pluripotent stem cell- and adult stem cell-derived cardiomyocytes. Although there are still problems that need to be addressed, studies up to date have shown promising results in recovering the lost cardiomyocytes and ultimately improving heart function after injury.作者: 領(lǐng)導(dǎo)權(quán) 時(shí)間: 2025-3-26 11:30 作者: 燈泡 時(shí)間: 2025-3-26 15:36 作者: lipids 時(shí)間: 2025-3-26 20:07 作者: Prostatism 時(shí)間: 2025-3-27 00:37 作者: 耕種 時(shí)間: 2025-3-27 02:43 作者: 會(huì)議 時(shí)間: 2025-3-27 06:07
Cardiovascular Regenerative Medicine: Challenges, Perspectives, and Future Directions, adult human heart possesses markedly restricted regenerative capacity. In many cases, a combination of these mechanisms is involved in healing the damaged tissue (e.g., paracrine effects or inducing innate therapeutic responses by implanted patch or cells) [8].作者: 一起平行 時(shí)間: 2025-3-27 10:20
Brand Fortner,Theodore E. Meyer disease and for assessing the cardiomyopathic and proarrhythmic risk of drugs. We review the current status of large-scale screening of iPSC-derived cardiomyocyte disease models and explore new advances in cell culture, three-dimensional engineered tissues, and instrumentation that might address cu作者: 生氣地 時(shí)間: 2025-3-27 15:34 作者: Neuralgia 時(shí)間: 2025-3-27 19:09
https://doi.org/10.1007/978-94-015-9578-0pathways in the heart, and numerous nanocarriers for targeted cardiac drug delivery have now been achieved. In this chapter we review the rationale for engineering biological tissues at the nanoscale as well as recent applications in nanofabrication and nanomedicine for cardiac regeneration.作者: 盡管 時(shí)間: 2025-3-28 01:52 作者: 搖曳的微光 時(shí)間: 2025-3-28 02:14 作者: narcissism 時(shí)間: 2025-3-28 07:11
Book 2019ional potential of current technologies such as cardiac patch-based treatments, cell-based regenerative therapies, and injectable hydrogels. The book examines how these methodologies are used to treat a variety of cardiovascular diseases including myocardial infarction, congenital heart disease, and作者: GUILT 時(shí)間: 2025-3-28 13:34
regenerative therapies, and injectable hydrogels. The book examines how these methodologies are used to treat a variety of cardiovascular diseases including myocardial infarction, congenital heart disease, and978-3-030-20049-7978-3-030-20047-3作者: 擴(kuò)張 時(shí)間: 2025-3-28 16:43
https://doi.org/10.1007/978-3-030-20047-33D bioprinting of cardiovascular tissues; Bioengineered cardiovascular tissues; Cardiac biomaterials; C作者: 光明正大 時(shí)間: 2025-3-28 22:09
978-3-030-20049-7Springer Nature Switzerland AG 2019作者: 身體萌芽 時(shí)間: 2025-3-29 00:03
Brand Fortner,Theodore E. Meyerers have used two-dimensional (2D) cell culture methods to elucidate the molecular mechanisms that drive diseases. However, this method of cell culture fails to recapitulate the complex, three-dimensional (3D) microenvironment that is present in vivo. Recently, tissue-engineered models have been gen作者: 長(zhǎng)處 時(shí)間: 2025-3-29 03:34
Brand Fortner,Theodore E. Meyer introduce or correct disease-causing mutations, creates unprecedented opportunities for drug discovery. The new technologies have the potential to revolutionize the drug development pipeline, from delineating disease mechanisms and discovery of therapeutic targets to library screening and validatio作者: Allure 時(shí)間: 2025-3-29 10:22
https://doi.org/10.1007/978-94-015-9578-0nt therapies are restricted to pharmaceuticals, mechanical and electrical support devices, and synthetic materials. Decellularized extracellular matrices have strong potential to provide support to failing myocardium. Their native composition offers complex biochemical cues beyond what can be synthe作者: FLING 時(shí)間: 2025-3-29 13:14 作者: 表兩個(gè) 時(shí)間: 2025-3-29 18:02
https://doi.org/10.1007/978-94-015-9578-0rgoing current treatment modalities is bleak, due to the lack of regenerative capacity of native heart tissue. Tissue engineering and regenerative medicine have developed numerous strategies to repair or replace injured myocardium. One of the most promising strategies to date is the attempt to engin作者: 性上癮 時(shí)間: 2025-3-29 20:19
https://doi.org/10.1007/978-94-015-9578-0 method that is used for the generation of defined biological products from living cells, biomaterials, bioactive molecules, and extracellular matrices. As one of the mainstream technical routes in biofabrication, bioassembly has been widely used for generating 3D cardiac microtissues. In this chapt作者: dapper 時(shí)間: 2025-3-30 01:18
https://doi.org/10.1007/978-94-015-9578-0egies and secondary interventions have led to enhanced survival, many patients still succumb to heart failure. This necessitates the development of novel strategies to target the microvascular dysfunction and malperfusion which lead to progressive functional deterioration. Cardiovascular tissue engi作者: NEEDY 時(shí)間: 2025-3-30 04:56 作者: 萬(wàn)靈丹 時(shí)間: 2025-3-30 10:17
https://doi.org/10.1007/BFb0096975on capability of adult cardiomyocytes, an injured heart is incapable of replacing its lost myocardium. Instead, the heart heals through formation of fibrotic scar tissue which, unlike cardiomyocytes, lacks contractile capability. This gradually weakens the heart and in the long term may result in he作者: Commentary 時(shí)間: 2025-3-30 16:18 作者: 6Applepolish 時(shí)間: 2025-3-30 19:25
